beat second tripl move pivot program
vertex report revenu beat consensu
kalydeco revenu beat consensu orkambi/symdeko
revenu orkambi symdeko beat consensu
overal total cf revenu y/i increas non-gaap
oper expens non-gaap ep beat consensu
vertex end period cash
guidanc vertex reiter guidanc cf revenu
oper expens non- oper expens
model adjust increas cf revenu estim
base increas revenu estim kalydeco
came net effect non-gaap ep estim
increas
anoth tripl goe pivot studi tezacaftor ivacaftor
initi one cf patient homozyg
heterozyg patient minim function mutat
het/min recal tripl tez/iva current two studi
popul two shot goal tripl
conclus vertex cf franchis continu grow compani
deliv anoth strong quarter expect growth continu
launch symdeko gain traction focu tripl could
posit vertex captur cf popul
tripl combin smaller shorter trial clinic trial get
smaller shorter vertex continu develop next-gen cf regimen tripl
combin back approv medicin particularli symdeko recal
orkambi studi enrol patient symdeko studi
enrol patient drug demonstr signific improv
lung function week symdeko backbon studi
het/min patient enrol patient four-week
efficaci safeti data safeti data collect
requir regulatori submiss support nda homozygot
studi tripl enrol patient four-week
efficaci follow four-week run-in period tez/iva safeti data
het/min studi support nda could see data later year
decis advanc pivot program base data
two studi demonstr signific increas percent predict
forc expiratori volum daili potenti move
addit dose rang studi support next wave tripl combin
symdeko launch underway us eu approv homozygot
patient least one mutat respons tez/iva iva expect
improv safeti profil orkambi patient may convert
symdeko symdeko reach homozyg patient inelig
orkambi well heterozyg patient
thousand except per share data
interest incom net
loss discontinu oper
net incom attribut vertex
compani report maxim group estim
